Practices are reminded that Black Country ICB are currently commissioning tirzepatide (Mounjaro®) for the management of obesity for an eligible cohort of people who meet the following criteria.

• Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds),
• And have obstructive sleep apnoea on CPAP (or where CPAP is not tolerated)
• And have at least three of the following long-term conditions:
  • Type 2 diabetes
  • High blood pressure (hypertension)
  • Cardiovascular disease
  • Dyslipidaemia.

Where patients meet the above criteria practices commencing patients on Tirzepatide should ensure that the Black Country weight management pathway is followed which includes referring the patient to the behaviour support for obesity programme (BSOP).